Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2016-06-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Appendix 3B - lapse of options 12 pages 529.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities. The content includes detailed information about securities issued or to be issued, terms of securities, shareholder approvals, and calculation of placement capacity under ASX Listing Rules. It is not a financial report, earnings release, or management discussion but rather a regulatory announcement about capital changes and securities issuance. Therefore, it fits the category of Share Issue/Capital Change announcements.
2016-06-13 English
App 3B - lapse of options correction 12 pages 529.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities. It includes detailed information about the class and number of securities issued or to be issued, terms of securities, issue price, purpose of the issue, and compliance with ASX listing rules. The document does not contain financial statements, management discussion, or earnings data. It is a regulatory announcement about capital changes, specifically new share issues and securities quotation. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a full regulatory filing of a capital change event.
2016-06-13 English
Phase 2 data presented to American Thoracic Society 2 pages 257.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX media announcement presenting phase 2 clinical trial data of a drug (INV102) for smoking cessation. It summarizes study results, safety data, and future development plans. The text is a public announcement of clinical trial data presented at a medical society meeting, not a full financial or regulatory report. It does not contain financial statements, regulatory certifications, or detailed management discussion. The document length is about 6,251 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Capital/Financing Update (CAP) because it relates to clinical trial progress and potential drug development partnerships, which are material updates relevant to investors and capital markets.
2016-05-19 English
Response to ASX Appendix 4C Query 5 pages 370.5KB
Regulatory Filings Classification · 95% confidence The document is a response letter from Invion Limited to the ASX Compliance regarding queries about the company's Appendix 4C quarterly cash flow report for the quarter ending 31 March 2016. The letter addresses questions about the company's cash flow situation, plans for raising capital, and compliance with ASX listing rules. The document references the Appendix 4C report but does not contain the report itself or detailed financial statements. It is a regulatory compliance communication related to a quarterly cash flow report, typical of an ASX query response. The document is not a full financial report like an Interim/Quarterly Report (IR) but rather a regulatory filing responding to a compliance query. Therefore, it fits best under Regulatory Filings (RNS). The document length (9443 characters) and content confirm it is not a brief announcement but a detailed regulatory response letter.
2016-05-08 English
Appendix 4C - quarterly 6 pages 271.8KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'APPENDIX 4C' for the quarter ending 31 March 2016. Appendix 4C is a standard quarterly cash flow report required by the ASX for entities admitted on the basis of commitments. The document contains detailed quarterly cash flow statements, business updates, and compliance statements. It is not a full annual or interim report but a quarterly cash flow report. The document length is over 10,000 characters, indicating it is the report itself, not just an announcement of a report. The content matches the definition of an Interim / Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the correct classification is IR with high confidence. Q1 2016
2016-04-28 English
End of Phase 2 Meeting for INV102 (nadolol) 2 pages 264.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX media announcement from Invion Limited regarding a successful meeting with the FDA to discuss Phase 3 development plans for their drug INV102. It contains no financial statements, no detailed financial data, nor is it a transcript or report of financial results. It is a regulatory update about drug development progress and regulatory interactions. The document is relatively short (4607 characters) and serves as a public announcement of a corporate development rather than a financial report or detailed investor presentation. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-04-03 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.